Tandem Diabetes Care, a global leader in insulin delivery and diabetes technology, has announced the U.S. launch of its t:slim X2 insulin pump featuring Control-IQ+ automated insulin delivery (AID) technology, now fully integrated with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. This marks the first phase of a global commercial rollout aimed at expanding options and personalization for people living with diabetes.
In the U.S., the updated software enabling FreeStyle Libre 3 Plus integration comes preloaded on all new t:slim X2 shipments and is also available to existing users via a free remote software update. The company plans to begin international early-access programs for this integrated system by the end of 2025, followed by full-scale global availability in 2026.
“With this integration, we expand the benefits of greater control to more people living with diabetes worldwide with our AID system that is easy to start, use, and personalize,” said John Sheridan, President and CEO of Tandem Diabetes Care. “It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott’s latest CGM sensor on our tested and trusted t:slim X2 insulin pump.”
The FreeStyle Libre 3 Plus is the world’s smallest CGM, transmitting automatic glucose readings every minute directly to the insulin pump and offering an extended 15-day wear time. The Control-IQ+ technology represents Tandem’s most advanced hybrid closed-loop algorithm yet—adjusting insulin delivery every five minutes based on predicted glucose levels. It is also the only system to feature AutoBolus, which automatically calculates and delivers correction doses, helping mitigate missed meal boluses and simplifying daily diabetes management.
Tandem will notify all eligible t:slim X2 users in the U.S. with detailed instructions to enable this new compatibility feature free of charge.
Also Read
